24/7 Market News Snapshot 12 February, 2025 – Xilio Therapeutics, Inc. Common Stock (NASDAQ:XLO)

February 12, 2025

DENVER, Colo., 12 February, 2025 (247marketnews.com) – (NASDAQ:XLO) are discussed in this article.
Xilio Therapeutics, Inc. has recently captured the attention of investors, with shares trading at approximately $1.593, reflecting a remarkable 142.47% increase from the previous closing price of $0.657. This surge is accompanied by a robust trading volume of 8.56 million shares, indicating heightened investor interest, potentially spurred by recent positive advancements in the company’s innovative therapies. Analysts are closely monitoring Xilio as it gains momentum, suggesting it may evolve into a significant player in the biotech arena.

In a pivotal move to bolster its oncology portfolio, Xilio has entered into a strategic collaboration with AbbVie to further develop tumor-activated immunotherapies. Through an option-to-license agreement, the partnership aims to harness Xilio’s proprietary technology, which focuses on creating advanced masked T-cell engagers and other novel immunotherapeutic approaches. The collaboration marks an important progression in both companies’ efforts to enhance cancer treatment methodologies.

Dr. Theodora S. Ross, Vice President of Early Oncology Research and Development at AbbVie, emphasized the partnership’s potential, asserting that it aims to lead to transformative treatments for cancer. Xilio’s Chief Scientific Officer, Uli Bialucha, also expressed optimism regarding the alliance, affirming that collaboration with a leader like AbbVie significantly boosts the advancement of their next-generation immunotherapy technologies.

The terms of the agreement highlight AbbVie’s strong commitment, with Xilio set to receive $52 million upfront, including a $10 million equity investment, alongside prospective contingent payments totaling up to approximately $2.1 billion. This significant backing reflects a shared confidence in the promising merger of expertise and innovation. An upcoming investor conference call is scheduled for today at 8:30 AM EST, where leadership will provide further insights into this high-visibility collaboration as both companies strive to revolutionize cancer therapies.

Related news for (XLO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.